The investment thesis highlights a preference for the GARP strategy, focusing on high-growth biotech companies like CRISPR Therapeutics, which has a promising product, CASGEVY, for severe genetic diseases. While robust pipeline potential suggests a fair value of $91.95 with 73% upside, significant risks include insurance coverage reliance and competition, warranting cautious investment.













